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Abstract
Background: low bone mineral density measured by dual-energy x-ray absorptiometry is associated with increased mortality.
The relationship between other skeletal phenotypes and mortality is unclear. The aim of this study was to determine the rela-
tionship between quantitative heel ultrasound parameters and mortality in a cohort of European men.
Methods: men aged 40–79 years were recruited for participation in a prospective study of male ageing: the European Male
Ageing Study (EMAS). At baseline, subjects attended for quantitative ultrasound (QUS) of the heel (Hologic—SAHARA) and
completed questionnaires on lifestyle factors and co-morbidities. Height and weight were measured. After a median of 4.3 years,
subjects were invited to attend a follow-up assessment, and reasons for non-participation, including death, were recorded. The re-
lationship between QUS parameters (broadband ultrasound attenuation [BUA] and speed of sound [SOS]) and mortality was
assessed using Cox proportional hazards model.
Results: from a total of 3,244 men (mean age 59.8, standard deviation [SD] 10.8 years), 185 (5.7%) died during the follow-up
period. After adjusting for age, centre, body mass index, physical activity, current smoking, number of co-morbidities and general
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health, each SD decrease in BUAwas associated with a 20% higher risk of mortality (hazard ratio [HR] per SD= 1.2; 95% confi-
dence interval [CI] = 1.0–1.4). Compared with those in higher quintiles (2nd–5th), those in the lowest quintile of BUA and SOS
had a greater mortality risk (BUA: HR= 1.6; 95% CI = 1.1–2.3 and SOS: HR= 1.6; 95% CI = 1.2–2.2).
Conclusion: lower heel ultrasound parameters are associated with increased mortality in European men.
Keywords: quantitative heel ultrasound, mortality, men, epidemiology, older people
Introduction
Data from observational studies suggest an association be-
tween low bone mineral density (BMD) assessed using bone
densitometry and mortality including all-cause and cardio-
vascular disease [1–4]. The mechanism is uncertain though is
thought in part to relate to adverse lifestyle factors linked
with reduced BMD and also mortality. Quantitative ultra-
sound (QUS) is associated with an increased risk of fracture
[5, 6]; however, less is known about other adverse outcomes
including mortality. Lower heel ultrasound parameters have
been associated with an increased mortality in some, though
not all, observational studies in postmenopausal women
[7–9]; however, to date, there are no data in men. We used
data from a large population-based study of ageing in men to
determine the association between QUS parameters and
mortality (both all-cause and attributable to cardiovascular
disease [CVD]), and whether the association can be ex-
plained by lifestyle or adverse health factors.
Methods
Subjects and study design
The subjects included in this analysis were recruited for parti-
cipation in the European Male Ageing Study (EMAS). Details
concerning the study design and recruitment have been previ-
ously described [10]. Briefly, an age-stratified probability
sample of 3,369 men aged 40–79 (mean ± SD: 60 ± 11) years
were recruited from population registers in eight European
centres (Florence, Italy; Leuven, Belgium; Malmö, Sweden;
Manchester, UK; Santiago de Compostela, Spain; Lódz,
Poland; Szeged, Hungary; Tartu, Estonia). The choice of
sampling frame was based on availability and representative-
ness of the local adult population within each centre and
included primary care registers (UK), population registers
and also electoral registers. The participation rate overall was
45% though there was some variation in rate by centre [10].
Subjects completed a postal questionnaire and then attended a
research clinic for further assessments which included a single
fasting morning (before 1,000 h) venous blood sample [10].
Subjects were subsequently invited to attend a follow-up
assessment and completed another postal questionnaire
(a median of 4.3 years later (range 3.0–5.7 years)). Those
who did not reply after the initial contact were sent a further
reminder. Ethical approval for the study was obtained in
accordance with local institutional requirements in each
centre. All subjects provided written informed consent.
Assessments
The postal questionnaire included questions concerning cur-
rent smoking, frequencyof alcohol consumption, general health
and whether subjects were currently being treated for a range
of 16 medical conditions (heart condition, hypertension, bron-
chitis, asthma, peptic ulcer, epilepsy, diabetes, liver condition,
diseases of the pituitary, testis, prostate, adrenal glands and
thyroid, cancer, stroke and fracture since the age of 25).
Physical activity was assessed using the Physical Activity Scale
for the Elderly (PASE) [11]. Serum 25-hydroxyvitamin D (25
(OH)D) levels were determined using a radioimmunoassay
(RIA kit; DiaSorin, Stillwater, MN, USA) as described previ-
ously [12]. Information was also collected on current medica-
tions. Height and body weight were measured in standardised
methods and body mass index (BMI) was calculated as weight
(kg) divided by the square of height (m).
QUS of the heel
QUS of the left heel was performed with the Sahara Clinical
Sonometer (Hologic, Inc., Bedford, MA, USA) using a stan-
dardised protocol in all centres. Outputs included broadband
ultrasound attenuation (BUA measured in dB/MHz) and
speed of sound (SOS measured in m/s). Short-term preci-
sion was measured by performing duplicate measurements in
20 randomly selected subjects from one centre (Leuven,
Belgium). The in vivo CVs were 2.8 and 0.3% for BUA and
SOS, respectively. Repeat measurements (n= 10) were per-
formed on a roving phantom at each of the eight centres.
Standardised CVs (SCVs) [13] for within machine variability
ranged by centre: for SOS, from 1.0 to 5.6%, and BUA from
0.7 to 2.7%. SCVs for between machine variability were
4.8% for BUA and 9.7% for SOS.
Mortality
Deaths that occurred during the follow-up period were initially
ascertained either through direct contact by relatives on receipt
of the postal questionnaire or, if this was not returned, by
further enquiry made to ascertain the subject’s vital status. The
enquiry procedure varied between centres and included review
of medical records/death registers and telephone follow-up.
Deaths were verified from: death certificates (28%), death reg-
isters (37%) and medical/hospital records (24%). Eleven per
cent of deaths were unverified and information from the
family member/contact person was the only source. Deaths
were categorised where possible as being due to CVD, cancer
or other causes, using where possible the same source as that
used to verify the death. Subjects who did not reply to the
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follow-up postal questionnaire and for whom no further infor-
mation was available were classified as ‘lost to follow-up’.
Statistical analysis
Subjects contributed follow-up time (person-years) from the
date of participation in the baseline survey to the point of
last contact, which was either the date of the follow-up
assessment or the date of death. All deaths occurring up to
31 December 2008 were included in this analysis. Body mass
index (BMI) was treated as a continuous variable and also
categorised into three groups: <20, 20–30 and 30 kg/m2 and
over. Smoking status was categorised as current, previous
and never. Poor general health was categorised as fair/
poor versus excellent/very good/good. Co-morbidity was
categorised as either none or one or more reported morbid
conditions. The QUS parameters were z-scored (per stand-
ard deviation [SD]), categorised also into quintiles and
further dichotomised into lowest and higher quintiles 2–5.
Differences in baseline characteristics between those who
died and survivors were assessed using the t-test and the
Wilcoxon rank-sum test as appropriate based on the under-
lying distribution of the variables. Cox proportional hazard
models were used to assess the association between putative
confounders and mortality (all-cause and CVD) adjusting
for age and centre. Hazard models were also used to assess
the association between the QUS parameters (per SD, cate-
gorised into quintiles and dichotomised as lowest quintile
versus higher quintile) and mortality (all-cause and CVD) ini-
tially unadjusted, then serially adjusting for age and centre,
then factors found to be associated with mortality in the
earlier analysis. Sub-analyses were conducted comparing sub-
jects under the age of 60 to those aged 60 and over, and also
excluding deaths in the first 6 months and also the first year
of follow-up. The results are reported as hazard ratios (HR)
and 95% confidence intervals (CIs). For all models, the
assumption of proportional hazards was tested using the
Schoenfeld residuals. All statistical tests were performed
using STATAversion 11.2 (http://www.stata.com).
Results
Subjects
A total of 3,244 men had complete baseline QUS data. During
a median of 4.3 years of follow-up (range 3.0–5.7), comprising
12,072 person-years, there were 185 deaths (5.7%). No infor-
mation about vital status was obtained in 411 subjects. The
baseline characteristics of the cohort, stratified by vital status at
the end of the follow-up period, are presented in Table 1.
Those who died were older (69.3 versus 59.2 years), had a lower
weight (79.6 versus 83.6 kg) and also had a lower PASE score.
A greater proportion of those who died smoked, consumed
alcohol less frequently, had at least one co-morbid condition
and were in fair or poor general health. Mean BUA (74.4 versus
80.4 dB/MHz) and SOS levels (1,538.8 versus 1,551.1 m/s)
were lower in those who died compared with survivors.
Mortality
Of the 185 deaths, 70 (37.8%) were considered related to
CVD and 71 (38.3%) related to cancer. Seven (3.8%) deaths
were attributable to both CVD and cancer. Of the remaining
deaths, 33 (17.8%) were from other causes and in 18 (9.7%)
the cause could not be determined. After adjustment for
centre, increasing age (per year) was associated with a 10%
higher risk in all-cause mortality (Table 2). After adjustment
for age and centre, increasing physical activity, as measured by
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Influence of age, anthropometry, lifestyle and general
health on all-cause and cardiovascular-related mortality
All-cause
mortality
CVD-related
mortality
Hazard ratioa (95% CI)
Age (years)b 1.1 (1.09–1.12)*** 1.1 (1.09–1.16)***
BMI (kg/m2) 0.97 (0.9–1.0) 1.0 (0.98–1.1)
BMI (kg/m2)
<20 2.4 (0.99–6.0) 1.7 (0.2–12.7)
20–30 Referent Referent
30+ 0.9 (0.6–1.3) 1.3 (0.8–2.2)
PASE score (per 100) 0.7 (0.5–0.8)*** 0.5 (0.4–0.8)**
Current smoker (yes versus no) 2.3 (1.7–3.3)*** 3.0 (1.7–5.2)***
Alcohol consumption/week
None 1.4 (0.9–2.2) 1.2 (0.6–2.6)
<1 day 0.9 (0.6–1.4) 0.9 (0.4–1.8)
1–2 days Referent Referent
3–4 days 0.7 (0.4–1.4) 0.5 (0.1–1.9)
5–6 days 0.6 (0.3–1.5) 0.3 (0.04–2.2)
Every day 1.2 (0.7–2.0) 1.1 (0.5–2.8)
Co-morbidities
None Referent Referent
One or more 2.3 (1.5–3.5)*** 4.5 (1.8–11.5)**
General health
Excellent/very good/good Referent Referent
Fair/poor 2.3 (1.6–3.2)*** 3.9 (2.1–7.5)***
aAdjusted for age and centre except badjusted for centre.
**P < 0.01.
***P < 0.001.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Baseline characteristics by vital status
Survived
(n= 2,648)
Died
(n= 185)
Pdiff
value
Mean (SD)
Age (years) 59.2 (10.6) 69.3 (8.3) <0.001
Height (cm) 174.0 (7.2) 170.1 (6.9) <0.001
Weight (kg) 83.6 (13.4) 79.6 (15.9) <0.001
BMI (kg/m2) 27.6 (3.9) 27.5 (4.8) NS
PASE score 200.6 (88.8) 141.5 (90.3) <0.001
QUS BUA (dB/MHz) 80.4 (17.8) 74.4 (20.3) <0.001
QUS SOS (m/s) 1,551.1 (31.7) 1,538.8 (34.1) <0.001
% %
Current smoker (yes versus no) 20.0 26.5 0.03
Alcohol consumption, >1 day/week 57.6 41.4 <0.001
≥1 co-morbidities versus none 49.7 84.9 <0.001
Fair/poor general health 29.5 63.0 <0.001
Pdiff using t-test or Wilcoxon rank-sum test.
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PASE score, was associated with a lower all-cause mortality. In
contrast, current smoking, the presence of at least one co-
morbid condition and fair/poor general health were associated
with higher all-cause mortality. There was no relationship
between BMI or alcohol consumption and mortality after ad-
justment for age and centre. Similar findings were observed
for deaths that were related to CVD disease (Table 2).
QUS and mortality
Table 3 shows the association between QUS parameters and
all-cause mortality. BUA (per SD decrease) was associated
with a higher risk of mortality (HR= 1.4 per unit change in
BUA), an effect that remained significant after adjustment for
age, centre, smoking, physical activity, co-morbidities and
general health (HR= 1.2; 95% CI = 1.0–1.4). A similar associ-
ation was observed with SOS, though after adjustment for life-
style and general health factors the CI just failed to exclude
unity (HR= 1.2; 95% CI = 0.99–1.4). When the QUS para-
meters were categorised into quintiles, compared with those in
the highest quintile of BUA or SOS, the risk of death was
highest in those in the lowest quintiles. This was significant
after adjustment for age and centre though the effect was atte-
nuated and became non-significant after further adjustment
for lifestyle and general health factors. There was no clear
dose–response effect. After further categorisation, compared
with those in quintiles 2–5, men in the lowest quintile of both
BUA and SOS were at significantly higher risk of mortality—
an effect that persisted after adjustment for confounders
(BUA, HR = 1.6; 95% CI = 1.1–2.3; SOS, HR= 1.6; 95%
CI = 1.2–2.2). This effect persisted after further adjustment
for serum 25(OH)D (data not shown). Broadly similar results
were evident for those deaths considered related to CVD (see
the Supplementary data, Table Appendix S1, available in Age
and Ageing online). Excluding men who died in the first 6
months (n= 10) or first year of follow-up (n= 23) made no
difference to the results (data not shown).
Discussion
In this population-based sample of middle aged and older
European men, lower BUA and SOS were associated with a
higher risk of mortality. Those in the lowest quintile of both
BUA and also SOS measurements had a 60% increased risk
of all-cause mortality—an effect that persisted after adjust-
ment for age, centre, lifestyle and general health factors. We
observed similar results for CVD-related mortality. In
keeping with many other studies, we identified smoking, low
physical activity, number of co-morbidities and poor general
health as predictors of mortality.
The relationship between low BMD and mortality has
been confirmed in many prospective studies. Using data
from the Study of Osteoporotic Fractures (SOF), Browner
et al. [1] reported an age-adjusted relative risk of 1.19 per each
SD reduction in proximal radius BMD as measured by
single-photon absorptiometry (95% CI = 1.04–1.36). The
authors suggested that low BMD was probably a marker
of the cumulative effect of many other variables that
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Influence of QUS parameters on all-cause mortality
Unadjusted Adjusted for age and centre Adjusted for age, centre,
current smoking, physical activity,
co-morbidities and general health
Hazard ratio (95% CI)
BUA (per SD decrease) 1.4 (1.2–1.6)*** 1.3 (1.1–1.5)** 1.2 (1.0–1.4)*
BUA quintiles: (dB/MHz)
5: >95.0 Referent Referent Referent
4: 83.9–95.0 1.2 (0.7–1.9) 1.0 (0.6–1.7) 0.9 (0.5–1.6)
3: 74.8–83.8 1.3 (0.8–2.2) 1.1 (0.7–1.9) 1.1 (0.6–1.9)
2: 65.5–74.7 1.0 (0.6–1.8) 1.0 (0.6–1.7) 0.8 (0.5–1.5)
1: <65.5 2.3 (1.5–3.6)*** 1.8 (1.2–2.9)* 1.5 (0.9–2.5)
BUA quintiles: (dB/MHz)
5/4/3/2: ≥65.5 Referent Referent Referent
1: <65.5 2.0 (1.5–2.7)*** 1.8 (1.3–2.5)*** 1.6 (1.1–2.3)**
SOS (per SD decrease) 1.5 (1.3–1.8)*** 1.3 (1.1–1.5)** 1.2 (0.99–1.4)
SOS quintiles: (m/s)
5: >1,574.7 Referent Referent Referent
4: 1,555.6–1,574.7 1.6 (0.9–2.7) 1.4 (0.8–2.4) 1.4 (0.8–2.5)
3: 1,538.7–1,555.5 1.3 (0.7–2.2) 1.1 (0.6–1.8) 0.9 (0.5–1.6)
2: 1,523.6–1,538.6 1.3 (0.8–2.3) 1.0 (0.6–1.7) 0.8 (0.5–1.5)
1: <1,523.6 3.1 (1.9–5.0)*** 2.0 (1.2–3.3)** 1.6 (0.9–2.8)
SOS quintiles: (m/s)
5/4/3/2: ≥1,523.6 Referent Referent Referent
1: <1,523.6 2.4 (1.8–3.3)*** 1.8 (1.3–2.5)*** 1.6 (1.2–2.2)**
*P < 0.05.
**P < 0.01.
***P < 0.001.
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influence mortality. Indeed, the association they observed
was no longer statistically significant in multivariable analyses
that included general health measures (such as self-reported
health status, muscle strength and current physical activity).
Interestingly, though in a model that included other predic-
tors of mortality that are less linked to bone status (diabetes
mellitus, hypertension and previous stroke), the association
remained significant [1]. In a further study, Johansson et al.
[2] also reported a 1.19-fold increase in mortality (95%
CI = 1.02–1.39) per 1 SD reduction in BMD as measured by
dual-photon absorptiometry at the calcaneus in women after
adjustment for blood pressure and serum lipids. The authors
considered that BMD is a predictor of survival independent
of other diseases, and a better predictor of death than blood
pressure or cholesterol. Kado et al. [3] studied the relationship
between mortality and the rate of bone loss as measured by
DXA, and found that women losing >2% per year at the hip
had a mortality risk about three times greater than those
losing <1%. Trivedi et al. [4] observed similar findings in
men. After adjusting for major cardiovascular risk factors,
they observed a 30% reduction in mortality per 1 SD in-
crease in DXA assessed BMD at the hip. In a further Danish
cohort [14], using single-photon absorptiometry at the distal
forearm, for each decrease of 1 SD in BMD, the risk of all-
cause mortality increased by 41% (relative risk [RR] = 1.4;
95% CI = 1.0–1.9).
Data from many studies suggest that BMD is not only
related to all-cause mortality but also to cardiovascular mor-
tality [1, 3, 4, 8, 15–18], vascular morbidity [19–21], cancer
[17] and deaths from other causes [17]. The reasons for this
are unclear, but the non-specificity in relation to mortality
suggests that low BMD may be a marker of poor overall
general health.
QUS parameters have been shown to predict fracture [5,
6, 22–25]; however, in contrast to findings in relation to
BMD, there are relatively fewer data linking QUS parameters
to mortality and no data in men. Bauer et al. [7] looked at the
association between BUA measured at the calcaneus and
total mortality in the Study of Osteoporotic Fractures. There
was a positive association with an HR of 1.16 (95%
CI = 1.07–1.26) for all-cause mortality. Pinheiro et al. [8] have
followed a small cohort of 275 elderly women for 5 years.
Each 1 SD reduction in stiffness index at baseline was signifi-
cantly associated with total mortality (HR = 1.57; 95%
CI = 1.10–2.47). Our data are broadly consistent with these
findings and extend them to a male cohort and suggest that
low QUS parameters in men are linked with an excess mor-
tality. There was an increased risk of both all cause and also
mortality from CVD, in keeping with data from the
European Prospective Investigation into Cancer and
Nutrition (EPIC)-Norfolk which reported that low heel
ultrasound parameters predicted incident heart failure in
men [26]. The association with mortality persisted after ad-
justment for lifestyle and also adverse health factors includ-
ing co-morbidity suggesting that these factors do not explain
the observed excess risk, though some caution is required in
interpreting these data—it is not possible for example to
exclude residual confounding or exposure misclassification
as a possible explanation.
The main strengths of our study were that it was pro-
spective, population-based and included data on a range of
putative confounders including lifestyle factors and co-
morbidities. There are a number of methodological limita-
tions to be considered. In our study, the overall loss to
follow-up rate was 9.9%. Compared with participants, those
lost to follow-up had lower 25(OH)D levels, physical func-
tion and mental processing speed [27]. Our findings may
therefore underestimate the true mortality experience of the
full cohort. However, health status did not differ in a system-
atic fashion between subjects who participated and those lost
to follow-up in relation to the QUS measurements. Thus,
losses to follow-up are unlikely to have influenced the main
findings in relation to the relationship between QUS para-
meters and mortality. The loss to follow-up rate varied across
the participating centres (4.4–16.3%), which may reflect
socio-cultural differences in the populations studied and also
the extent to which the losses to follow-up were traced at dif-
ferent centres. Adjusting for the effect of centre in the ana-
lysis did not, however, alter the main findings. Furthermore,
when the analysis was restricted to centres with >85%
follow-up, the results remained unchanged.
In summary, in this population-based sample of middle
aged and older European men, lower quantitative ultrasound
parameters of the heel are associated with an increased risk
of mortality. This was not explained by the occurrence of
lifestyle factors or the presence of co-morbidities.
Key points
• Those in the lowest quintile of QUS measurements had a
60% increased risk of all-cause mortality.
• The increase in risk of mortality persisted after adjustment
for lifestyle factors and the presence of co-morbidities.
• Smoking, low physical activity, number of co-morbidities
and poor general health were also found to be predictors of
mortality.
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Abstract
Objectives: the aim of this study is to know the prevalence of sarcopenia in geriatric outpatient clinics using the EGWSOP
(European Working Group on Sarcopenia in Older People) diagnostic criteria that include muscle mass, muscle strength and physic-
al performance.
Methods: subjects over 69 years old, able to walk without help and who attended five geriatric outpatient clinics were recruited.
Body composition was assessed using bioimpedance analysis (BIA), grip strength using a JAMAR dynamometer and physical per-
formance by the 4 m gait speed. Sarcopenia was diagnosed using the EGWSOP criteria (gait speed <0.8 m/s; grip strength <30 kg
in men or <20 kg in women, and muscle mass index (MMI) <8.31 kg/m2 in men or <6.68 kg/m2 in women).
Results: two hundred and ninety-eight subjects were included (median age 83.2 years, 63.1% women). 19.1% had sarcopenia
(12.7% men, 22.9% women); 20.1% had low muscle mass; 68.8% had low gait speed and 81.2% low grip strength. Only 21.9% of
the subjects with low grip strength and 19.5% of those with low gait speed had sarcopenia. No correlations between muscle mass
and either muscle strength or gait speed were detected.
Conclusions: sarcopenia is present in one out of five subjects attending geriatric outpatient clinics.
Keywords: sarcopenia, screening, older people, outpatient
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